Blueprint Medicines Corporation Interest Expense 2011-2026 | BPMC

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Blueprint Medicines Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
656 K	-946 K	2 M	-1.49 M	-366 K	-100 K	-180 K	-76 K	551 K	-429 K	-98 K	226 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2 M	-1.49 M	-20.6 K

Quarterly Interest Expense Blueprint Medicines Corporation

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
461 K	-	587 K	-1 K	376 K	-	-728 K	-626 K	986 K	-	396 K	632 K	-453 K	-	-522 K	-373 K	-214 K	-	-192 K	-23 K	-201 K	-	-72 K	-42 K	-44 K	-	2.8 M	2.44 M	2.39 M	-	954 K	861 K	425 K	-	158 K	131 K	61 K	-	6 K	-405 K	-37 K	-	-94 K	1 K	18 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.8 M	-728 K	284 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Graybug Vision GRAY	268 K	-	-11.23 %	$ 9.65 M	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.64	-1.89 %	$ 1.09 B	Canada
ADMA Biologics ADMA	-212 K	$ 16.45	0.43 %	$ 3.92 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
ANI Pharmaceuticals ANIP	-4.03 M	$ 76.75	0.85 %	$ 1.48 B	USA
Apellis Pharmaceuticals APLS	-133 K	$ 19.93	-1.14 %	$ 2.51 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
AVEO Pharmaceuticals AVEO	1.6 M	-	-	$ 521 M	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Axsome Therapeutics AXSM	-15.9 M	$ 163.82	-0.14 %	$ 8.15 B	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
BridgeBio Pharma BBIO	43.1 M	$ 66.98	3.8 %	$ 12.8 B	USA
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA
Avid Bioservices CDMO	4.34 M	-	-	$ 789 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-257 K	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
BioLineRx Ltd. BLRX	9.07 M	$ 2.88	2.51 %	$ 908 M	Israel
Clovis Oncology CLVS	444 K	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
BioMarin Pharmaceutical BMRN	15.3 M	$ 60.75	3.79 %	$ 11.7 B	USA
CTI BioPharma Corp. CTIC	13.1 M	-	-	$ 1.2 B	USA
CohBar CWBR	223 K	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	52 K	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	52 K	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Capricor Therapeutics CAPR	399 K	$ 25.71	-0.5 %	$ 688 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Codexis CDXS	-10.4 M	$ 1.1	12.24 %	$ 80.7 M	USA
Certara CERT	6.34 M	$ 7.33	1.24 %	$ 1.18 B	USA
Evofem Biosciences EVFM	2.27 M	-	7.55 %	$ 38.1 M	USA